ERBB2 and breast carcinoma: In immunocompromised female NOD/SCID mice with HER2-overexpressing human breast cancer xenografts, treatment with trastuzumab-AuNP-177Lu for 16 days resulted in significant inhibition of tumor growth compared with AuNP-177Lu-exposed or untreated mice.